Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia

Following the recent publication of Canadian evidence-based guidelines for frontline treatment of chronic lymphocytic leukemia (CLL), the same group of clinicians developed guidelines for CLL in the relapsed/refractory (R/R) setting. The treatment of R/R CLL has changed significantly in the past few...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2023-10, Vol.133, p.107372-107372, Article 107372
Main Authors: Owen, Carolyn, Eisinga, Sarah, Banerji, Versha, Johnson, Nathalie, Gerrie, Alina S., Aw, Andrew, Chen, Christine, Robinson, Sue
Format: Article
Language:English
Subjects:
CLL
Guidelines
Refractory
Relapse
SLL
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Following the recent publication of Canadian evidence-based guidelines for frontline treatment of chronic lymphocytic leukemia (CLL), the same group of clinicians developed guidelines for CLL in the relapsed/refractory (R/R) setting. The treatment of R/R CLL has changed significantly in the past few years, with many novel therapeutics available to hematologists across the country. These guidelines aim to standardize the management of CLL in the relapsed/refractory setting, using the best evidence currently available. •Most published trials in R/R CLL do not include patients treated with currently recommended firstline therapies.•BTK inhibitors are highly effective therapies for R/R CLL with second generation BTKi’s preferred due to reduced toxicity.•Venetoclax and rituximab (VEN-R) is also a highly effective therapy for R/R CLL with the advantage of being fixed-duration.•No studies have been performed to determine the best sequencing of novel therapies in patients with R/R CLL.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2023.107372